Which has better valuation & earnings, TMDX or SGP?

TransMedics Group has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransMedics Group $605.49M 3.91 $190.29M $4.40 15.55 Spyglass Pharma N/A N/A N/A N/A N/A

Which has better valuation & earnings, ESTA or SGP?

Spyglass Pharma has lower revenue, but higher earnings than Establishment Labs. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Establishment Labs $211.08M 12.32 -$51.06M -$1.49 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Which has higher earnings and valuation, AXGN or SGP?

Spyglass Pharma has lower revenue, but higher earnings than AxoGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AxoGen $238.11M 10.03 -$15.70M -$0.64 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Which has preferable valuation & earnings, LMAT or SGP?

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LeMaitre Vascular $249.60M 8.76 $57.73M $2.71 35.30 Spyglass Pharma N/A N/A N/A N/A N/A

Which has better valuation & earnings, BFLY or SGP?

Spyglass Pharma has lower revenue, but higher earnings than Butterfly Network. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Butterfly Network $97.61M 22.97 -$77.06M -$0.30 N/A Spyglass Pharma N/A N/A N/A N/A N/A

Spyglass Pharma (SGP) Competitors

$21.18 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$21.18 0.00 (0.00%)

As of 08:39 AM Eastern

Compare

SGP vs. TMDX, ESTA, AXGN, LMAT, and BFLY

Should you buy Spyglass Pharma stock or one of its competitors? MarketBeat compares Spyglass Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Spyglass Pharma include TransMedics Group (TMDX), Establishment Labs (ESTA), AxoGen (AXGN), LeMaitre Vascular (LMAT), and Butterfly Network (BFLY). These companies are all part of the "medical equipment" industry.

How does Spyglass Pharma compare to TransMedics Group?

TransMedics Group (NASDAQ:TMDX) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, analyst recommendations, media sentiment, earnings, dividends and profitability.

TransMedics Group presently has a consensus target price of $134.50, suggesting a potential upside of 96.52%. Spyglass Pharma has a consensus target price of $45.00, suggesting a potential upside of 112.46%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than TransMedics Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	0 Sell rating(s)	7 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.46
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

TransMedics Group has a net margin of 27.04% compared to Spyglass Pharma's net margin of 0.00%. TransMedics Group's return on equity of 22.38% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Spyglass Pharma	N/A	N/A	N/A

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

TransMedics Group has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	3.91	$190.29M	$4.40	15.55
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, TransMedics Group had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for TransMedics Group and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat TransMedics Group's score of 0.63 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
TransMedics Group	Positive
Spyglass Pharma	Very Positive

Summary

TransMedics Group beats Spyglass Pharma on 8 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, media sentiment and dividends.

72.9% of Establishment Labs shares are held by institutional investors. 10.0% of Establishment Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Establishment Labs had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 4 mentions for Establishment Labs and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Establishment Labs' score of 0.66 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Establishment Labs	Positive
Spyglass Pharma	Very Positive

Spyglass Pharma has lower revenue, but higher earnings than Establishment Labs.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	12.32	-$51.06M	-$1.49	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Spyglass Pharma has a net margin of 0.00% compared to Establishment Labs' net margin of -19.05%. Spyglass Pharma's return on equity of 0.00% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
Spyglass Pharma	N/A	N/A	N/A

Establishment Labs currently has a consensus price target of $87.14, indicating a potential downside of 1.40%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 112.46%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Spyglass Pharma beats Establishment Labs on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to AxoGen?

AxoGen (NASDAQ:AXGN) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, media sentiment, dividends, profitability, analyst recommendations, institutional ownership and risk.

Spyglass Pharma has a net margin of 0.00% compared to AxoGen's net margin of -13.21%. Spyglass Pharma's return on equity of 0.00% beat AxoGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AxoGen	-13.21%	-9.63%	-6.26%
Spyglass Pharma	N/A	N/A	N/A

Spyglass Pharma has lower revenue, but higher earnings than AxoGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AxoGen	$238.11M	10.03	-$15.70M	-$0.64	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

80.3% of AxoGen shares are held by institutional investors. 2.4% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

AxoGen presently has a consensus target price of $46.50, indicating a potential upside of 3.49%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 112.46%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts clearly believe Spyglass Pharma is more favorable than AxoGen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AxoGen	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, AxoGen had 2 more articles in the media than Spyglass Pharma. MarketBeat recorded 3 mentions for AxoGen and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat AxoGen's score of 1.30 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
AxoGen	Positive
Spyglass Pharma	Very Positive

Summary

Spyglass Pharma beats AxoGen on 6 of the 11 factors compared between the two stocks.

How does Spyglass Pharma compare to LeMaitre Vascular?

LeMaitre Vascular (NASDAQ:LMAT) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

LeMaitre Vascular has a net margin of 24.35% compared to Spyglass Pharma's net margin of 0.00%. LeMaitre Vascular's return on equity of 15.36% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LeMaitre Vascular	24.35%	15.36%	9.78%
Spyglass Pharma	N/A	N/A	N/A

LeMaitre Vascular currently has a consensus price target of $112.60, indicating a potential upside of 17.71%. Spyglass Pharma has a consensus price target of $45.00, indicating a potential upside of 112.46%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts clearly believe Spyglass Pharma is more favorable than LeMaitre Vascular.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LeMaitre Vascular	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

In the previous week, LeMaitre Vascular had 3 more articles in the media than Spyglass Pharma. MarketBeat recorded 4 mentions for LeMaitre Vascular and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat LeMaitre Vascular's score of 1.24 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
LeMaitre Vascular	Positive
Spyglass Pharma	Very Positive

84.6% of LeMaitre Vascular shares are held by institutional investors. 7.4% of LeMaitre Vascular shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

LeMaitre Vascular has higher revenue and earnings than Spyglass Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LeMaitre Vascular	$249.60M	8.76	$57.73M	$2.71	35.30
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

Summary

LeMaitre Vascular beats Spyglass Pharma on 8 of the 12 factors compared between the two stocks.

How does Spyglass Pharma compare to Butterfly Network?

Butterfly Network (NYSE:BFLY) and Spyglass Pharma (NASDAQ:SGP) are both medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Spyglass Pharma has a net margin of 0.00% compared to Butterfly Network's net margin of -73.63%. Spyglass Pharma's return on equity of 0.00% beat Butterfly Network's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Butterfly Network	-73.63%	-34.41%	-23.91%
Spyglass Pharma	N/A	N/A	N/A

Butterfly Network presently has a consensus target price of $5.56, indicating a potential downside of 36.82%. Spyglass Pharma has a consensus target price of $45.00, indicating a potential upside of 112.46%. Given Spyglass Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Spyglass Pharma is more favorable than Butterfly Network.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Butterfly Network	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyglass Pharma	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83

37.9% of Butterfly Network shares are owned by institutional investors. 22.0% of Butterfly Network shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Spyglass Pharma has lower revenue, but higher earnings than Butterfly Network.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Butterfly Network	$97.61M	22.97	-$77.06M	-$0.30	N/A
Spyglass Pharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Butterfly Network had 10 more articles in the media than Spyglass Pharma. MarketBeat recorded 11 mentions for Butterfly Network and 1 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 1.89 beat Butterfly Network's score of 0.29 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Butterfly Network	Neutral
Spyglass Pharma	Very Positive

Summary

Spyglass Pharma beats Butterfly Network on 7 of the 11 factors compared between the two stocks.

Get Spyglass Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGP vs. The Competition

Export

Metric	Spyglass Pharma	Surgical, Medical, And Dental Instruments And Supplies Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$708.11M	$2.93B	$4.35B	$12.17B
Dividend Yield	N/A	N/A	12.97%	6.11%
P/E Ratio	N/A	14.53	22.01	24.17
Price / Sales	N/A	287.70	165.14	99.03
Price / Cash	N/A	8.48	36.62	36.93
Price / Book	N/A	5.97	13.63	6.38
Net Income	N/A	$7.39M	$113.19M	$337.00M
7 Day Performance	9.51%	-1.37%	-0.98%	-0.23%
1 Month Performance	9.97%	-8.78%	-3.41%	-1.40%
1 Year Performance	N/A	-27.93%	11.96%	27.76%

Spyglass Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGP Spyglass Pharma	N/A	$21.18 flat	$45.00 +112.5%	N/A	$708.11M	N/A	N/A	65	Positive News Gap Down High Trading Volume
TMDX TransMedics Group	4.2421 of 5 stars	$74.37 -1.5%	$134.50 +80.9%	-47.9%	$2.57B	$605.49M	16.88	210
ESTA Establishment Labs	1.3562 of 5 stars	$86.64 +0.7%	$87.14 +0.6%	+115.9%	$2.55B	$211.08M	N/A	1,004
AXGN AxoGen	1.9436 of 5 stars	$45.33 +0.8%	$46.50 +2.6%	+327.9%	$2.41B	$238.11M	N/A	450	Positive News
LMAT LeMaitre Vascular	4.671 of 5 stars	$91.88 +3.7%	$112.60 +22.6%	+15.9%	$2.10B	$249.60M	33.95	490	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGP) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, ESTA, AXGN, LMAT, and BFLY

How does Spyglass Pharma compare to TransMedics Group?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Summary

How does Spyglass Pharma compare to AxoGen?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Summary

How does Spyglass Pharma compare to Butterfly Network?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Spyglass Pharma (SGP) Competitors

SGP vs. TMDX, ESTA, AXGN, LMAT, and BFLY

How does Spyglass Pharma compare to TransMedics Group?

Do analysts recommend TMDX or SGP?

Is TMDX or SGP more profitable?

Do insiders & institutionals believe in TMDX or SGP?

Which has better valuation & earnings, TMDX or SGP?

Does the media favor TMDX or SGP?

Summary

How does Spyglass Pharma compare to Establishment Labs?

Do institutionals and insiders have more ownership in ESTA or SGP?

Does the media refer more to ESTA or SGP?

Which has better valuation & earnings, ESTA or SGP?

Is ESTA or SGP more profitable?

Do analysts prefer ESTA or SGP?

Summary

How does Spyglass Pharma compare to AxoGen?

Is AXGN or SGP more profitable?

Which has higher earnings and valuation, AXGN or SGP?

Do insiders and institutionals have more ownership in AXGN or SGP?

Do analysts rate AXGN or SGP?

Does the media refer more to AXGN or SGP?

Summary

How does Spyglass Pharma compare to LeMaitre Vascular?

Is LMAT or SGP more profitable?

Do analysts recommend LMAT or SGP?

Does the media favor LMAT or SGP?

Do insiders & institutionals have more ownership in LMAT or SGP?

Which has preferable valuation & earnings, LMAT or SGP?

Summary

How does Spyglass Pharma compare to Butterfly Network?

Is BFLY or SGP more profitable?

Do analysts rate BFLY or SGP?

Do institutionals and insiders have more ownership in BFLY or SGP?

Which has better valuation & earnings, BFLY or SGP?

Does the media favor BFLY or SGP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGP vs. The Competition

Spyglass Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools